Reid Robison is CEO and Co-Founder at Tute Genomics.
Dr. Robison is a board-certified psychiatrist, with fellowship training in both neurodevelopmental genetics and bioinformatics.
After residency and fellowship training at the University of Utah, Dr. Robison joined as tenure track faculty where he co-directed a molecular genetics lab, studying the genetic basis of autism and other neurodevelopmental disorders, using next-generation sequencing technology.
Dr. Robison has led over $10 million in pharmaceutical studies, and previously founded Clinical Methods, an innovative, data-driven Phase I-IV CNS trials site that was later acquired.
Dr. Robison is also co-founder of Anolinx, a healthcare data analytics firm that was acquired in 2012.
|Oct 12, 2016||Business Wire - PierianDx Acquires Tute Genomics|
|Nov 2, 2015||PRNewswire All - Tute Genomics Acquires Knome|
|Nov 2, 2015||Xconomy - Bought By Utah Rival Tute, Former Genomics High Flyer Knome Bows Out|
|Nov 2, 2015||Silicon Slopes - News - Tute Genomics acquires Knome to further genome research|
|Jun 16, 2015||FinSMEs - FinSMEs|
|Apr 14, 2015||WSJ Blogs - Accelerator StartUp Health Launches Crowdfunding Syndicate on AngelList|
|Dec 4, 2014||Venture Beat - Tute Genomics raises $2.3M for genome analytics platform|